Obstetric anal sphincter injury: a follow-up questionnaire study on longer-term outcomes

Introduction and hypothesis Obstetric anal sphincter injuries (OASIS) contribute significantly to the development of anal incontinence (AI) in women. The aim of this study was to establish the incidence of AI after OASIS and to study the influence on the quality of life (QoL) in patients with OASIS....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International Urogynecology Journal 2016-10, Vol.27 (10), p.1591-1596
Hauptverfasser: Cornelisse, Simone, Arendsen, Linda Petra, van Kuijk, Sander Martijn Job, Kluivers, Kirsten Birgit, van Dillen, Jeroen, Weemhoff, Mirjam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction and hypothesis Obstetric anal sphincter injuries (OASIS) contribute significantly to the development of anal incontinence (AI) in women. The aim of this study was to establish the incidence of AI after OASIS and to study the influence on the quality of life (QoL) in patients with OASIS. Methods This cohort study, with prospective case-control follow-up, involves women who were treated for OASIS between 2005 and 2012 in two academic medical centers in The Netherlands. Three hundred and thirteen patients and 780 controls were invited to complete a validated questionnaire (Defecation Distress Inventory, Wexner Incontinence Score, and Fecal Instrument Quality of Life) regarding symptoms and bother of AI subsequent and QoL after delivery. The main outcome measures were the presence of AI and the impact on QoL. Results The questionnaire was completed by 141 patients and 194 controls. Mean follow-up was 4 years (range 1–9 years) in both groups. In the patient group, 55 women (39 %) reported AI symptoms compared with 38 women (20 %) in the control group (odds ratio 2.7, 95 % confidence interval 1.66–4.47, p  
ISSN:0937-3462
1433-3023
DOI:10.1007/s00192-016-3017-5